For the NO
DOI:
https://doi.org/10.47196/diab.v56i3Sup.532Keywords:
diabetes mellitus, insulinAbstract
The addition of metformin in adults with type 1 diabetes caused small reductions in body weight and lipid levels but did not improve HbA1c.
The trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide, showing modest HbA1c reductions (0.3 - 0.4%), decreases in weight ( 5 kg), and reductions in insulin doses (10 – 12%). The most frequent AEs with liraglutide were nausea and vomiting. The rate of symptomatic hypoglycemic episodes was increased with liraglutide 1.8 mg and 1.2 mg versus placebo. The rate of hyperglycemic episodes accompanied by ketosiswas increased with liraglutide 1.8 mg.
References
I. Dejgaard T, et al. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the randomized controlled trials. Diabetes Obes Metab 2021;23:2752-2762.
II. Buse J, Garg S, Rosenstock J. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American inTandem1 Study. Diabetes Care 2018;41:1970-1980.
III. Danne T, Cariou B, Banks P, Brandle M. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: The European inTandem 2 Study. Diabetes Care 2018;41:1981-1990.
IV. Phillip M, Mathieu C, et al. Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies outcomes from the DEPICT‐1 and -2 studies. Diabetes, Obesity and Metabolism 2021;23(2):549-560.
V. Rosenstock J, Marquad J, Laffel Lea. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE Trials. Diabetes Care 2018;41:2560-2569.
VI. Henry R, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozina, a sodium-glucose cotransporter 2 inhibitor, add-on to insulin in patientes with type 1 diabetes. Diabetes Care 2015;38:2285-2265.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
